share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/14 22:34

Moomoo AI 已提取核心信息

60 Degrees Pharmaceuticals reported Q2 2024 product revenues of $124,972, up 110% from $59,532 in Q2 2023, driven by strong growth in Arakoda sales. Gross profit improved to $35,408 compared to a loss of $124,445 last year, with gross margin reaching 28.3%. U.S. pharmaceutical distributor accounted for 92% of net product sales.Operating expenses increased significantly to $4.2 million from $667K in Q2 2023, primarily due to $2.6 million in R&D costs related to the Kentucky Technology report and $390K for the planned babesiosis trial. General and administrative expenses rose to $1.1 million driven by higher compensation, insurance, and investor outreach costs.The company ended the quarter with $1.6 million in cash. Management estimates current funds will sustain operations through March 2025, excluding costs for commercial programs and clinical trials. The company recently raised additional capital through an ATM offering in July-August 2024, selling 677,819 shares for proceeds of $2 million. A 1:12 reverse stock split was implemented in August 2024 to address Nasdaq listing requirements.
60 Degrees Pharmaceuticals reported Q2 2024 product revenues of $124,972, up 110% from $59,532 in Q2 2023, driven by strong growth in Arakoda sales. Gross profit improved to $35,408 compared to a loss of $124,445 last year, with gross margin reaching 28.3%. U.S. pharmaceutical distributor accounted for 92% of net product sales.Operating expenses increased significantly to $4.2 million from $667K in Q2 2023, primarily due to $2.6 million in R&D costs related to the Kentucky Technology report and $390K for the planned babesiosis trial. General and administrative expenses rose to $1.1 million driven by higher compensation, insurance, and investor outreach costs.The company ended the quarter with $1.6 million in cash. Management estimates current funds will sustain operations through March 2025, excluding costs for commercial programs and clinical trials. The company recently raised additional capital through an ATM offering in July-August 2024, selling 677,819 shares for proceeds of $2 million. A 1:12 reverse stock split was implemented in August 2024 to address Nasdaq listing requirements.
60度药品公司报告了2024年第二季度的产品收入为124,972美元，较2023年第二季度的59,532美元增长了110%，这主要得益于阿拉科达销售的强劲增长。毛利润改善至35,408美元，而去年则出现了124,445美元的损失，毛利率达到28.3%。美国药品分销商占净产品销售的92%。营业费用显著增加至420万，由2023年第二季度的66.7万增长，主要由于科技报告相关的260万研发成本和计划中的巴贝斯虫病试验的39万费用。一般和管理费用因工资、保险和投资者推广费用的增加而上升至110万。公司在本季度结束时现金为160万。管理层估计当前的所有基金类型将支持运营至2025年3月，但不包括商业项目和临床试验的成本。公司最近通过在2024年7月至8月期间的ATM发行重新融资，出售677,819股股票，所得款项为200万。为了满足纳斯达克上市要求，2024年8月实施了1:12的反向股票拆分。
60度药品公司报告了2024年第二季度的产品收入为124,972美元，较2023年第二季度的59,532美元增长了110%，这主要得益于阿拉科达销售的强劲增长。毛利润改善至35,408美元，而去年则出现了124,445美元的损失，毛利率达到28.3%。美国药品分销商占净产品销售的92%。营业费用显著增加至420万，由2023年第二季度的66.7万增长，主要由于科技报告相关的260万研发成本和计划中的巴贝斯虫病试验的39万费用。一般和管理费用因工资、保险和投资者推广费用的增加而上升至110万。公司在本季度结束时现金为160万。管理层估计当前的所有基金类型将支持运营至2025年3月，但不包括商业项目和临床试验的成本。公司最近通过在2024年7月至8月期间的ATM发行重新融资，出售677,819股股票，所得款项为200万。为了满足纳斯达克上市要求，2024年8月实施了1:12的反向股票拆分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间